Werewolf Therapeutics Statistics
Want to see HOWL full AI Analyst Report?
Werewolf Therapeutics (HOWL) Stock Statistics & Valuation Metrics
Total Valuation
Werewolf Therapeutics has a market cap or net worth of $51.03M. The enterprise value is $2.95M.
- Market Cap
- $51.03M
- Enterprise Value
- $2.95M
Share Statistics
Werewolf Therapeutics has 48,599,068 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 48,599,068
- Owned by Insiders
- 20.31%
- Owned by Institutions
- 14.42%
Financial Efficiency
Werewolf Therapeutics’s return on equity (ROE) is -2.45 and return on invested capital (ROIC) is -173.37%.
- Return on Equity (ROE)
- -2.45
- Return on Assets (ROA)
- -0.88
- Return on Invested Capital (ROIC)
- -173.37%
- Return on Capital Employed (ROCE)
- -1.82
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.56M
- Employee Count
- 39
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Werewolf Therapeutics is -1.79. Werewolf Therapeutics’s PEG ratio is -0.02.
- PE Ratio
- -1.79
- PS Ratio
- 2.38
- PB Ratio
- 7.41
- Price to FCF
- -2.09
- Price to Operating Cash Flow
- -2.09
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Werewolf Therapeutics had revenue of 0 and earned -60.82M in profits. Earnings per share was -1.32.
- Revenue
- 0
- Gross Profit
- -1.63M
- Operating Income
- -60.68M
- Pretax Income
- -60.82M
- Net Income
- -60.82M
- EBITDA
- -53.91M
- Earnings Per Share (EPS)
- -1.32
Cash Flow
In the last 12 months, operating cash flow was -23.96M and capital expenditures 0, giving a free cash flow of -23.96M billion.
- Operating Cash Flow
- -23.96M
- Free Cash Flow
- -23.96M
- Free Cash Flow per Share
- -0.49
Dividends & Yields
Werewolf Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -48.33%
- Earnings Yield
- -56.73%
Stock Price Statistics
- Beta
- 1.42
- 52-Week Price Change
- 12.57%
- 50-Day Moving Average
- 0.98
- 200-Day Moving Average
- 0.70
- Relative Strength Index (RSI)
- 53.99
- Average Volume (3m)
- 6.38M
Important Dates
Werewolf Therapeutics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Werewolf Therapeutics as a current ratio of 1.62, with Debt / Equity ratio of 38.04%
- Current Ratio
- 1.62
- Quick Ratio
- 1.62
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.90
- Interest Coverage Ratio
- -11.50
Taxes
In the past 12 months, Werewolf Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Werewolf Therapeutics EV to EBITDA ratio is -0.50, with an EV/FCF ratio of -0.32.
- EV to Sales
- 0.37
- EV to EBITDA
- -0.50
- EV to Free Cash Flow
- -0.32
- EV to Operating Cash Flow
- -0.32
Balance Sheet
Werewolf Therapeutics has $41.87M in cash and marketable securities with $0.00 in debt, giving a net cash position of $41.87M billion.
- Cash & Marketable Securities
- $41.87M
- Total Debt
- $0.00
- Net Cash
- $41.87M
- Net Cash Per Share
- $0.86
- Tangible Book Value Per Share
- $0.14
Margins
Gross margin is 80.41%, with operating margin of -90.91%, and net profit margin of -133.90%.
- Gross Margin
- 80.41%
- Operating Margin
- -90.91%
- Pretax Margin
- -133.90%
- Net Profit Margin
- -133.90%
- EBITDA Margin
- -73.20%
- EBIT Margin
- -94.69%
Analyst Forecast
The average price target for Werewolf Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 64.23%
Scores
- Smart Score
- 4
- AI Score
- 50

